Predictive Biosciences completed a $25 million Series C round, saying it plans to use the money to complete clinical trials for its CertNDx bladder cancer assay and ready it for market.
Latest News on MassDevice
Covidien to pay $250 million for Somanetics
Covidien plc (NYSE:COV) continued to streamline its medical device operations with the latest acquisition in a series of buys and sells: a $250 million cash buyout of oximetry equipment maker Somanetics Corp. (NSDQ:SMTS).
The Mansfield, Mass.-based medical products conglomerate agreed to pay $25 per share, or $250 million, for Troy, Mich.-based Somanetics.
Understanding the Basic Principles of Selling Your Home
Do you want to sell your house? Valuing a property for a successful sale consists of: depersonalizing the home as much as possible so that visitors can project how they want it to look (for this, you may want to call on a professional home stager); cleaning the house in every corner of the residence; […]
GE Healthcare launches web-based EMRs
GE Healthcare today unveiled a web-based electronic medical records solution.
The company’s Centricity Advance combines of EMR, practice management and patient portal solutions.
Using their own secure password, patients can log in from anywhere to schedule their appointments, request prescription refills or access billing statements, lab results and private messages from their clinicians, according to GE Healthcare.
EClinicalWorks expands Westborough headquarters
EClinicalWorks purchased a 100,000-square-foot facility to expand its headquarters in Westborough, Mass.
The electronic medical records and medical practice management company said the new offices, slated for completion in early 2011, will allow it to add staff.
The company has the "largest Software as a Service (SaaS) network in the industry," and "the building will permit immediate and future growth," said EClinicalWorks CEO Girish Kumar Navani in prepared remarks.
Parexel taps former regulatory officials for consulting group
Waltham-based contract research organization Parexel International Corp. (NSDQ:PRXL) hired two former regulatory scientists for its Parexel Consulting division.
The company added Dr. Toby Silverman, who oversaw aspects of the Food & Drug Administration’s Center for Biologics Evaluation and Research, and Keith Watson, a former employee of the U.K.’s Medicines and Healthcare products Regulatory Agency, where he was a liaison to several European biotechnology safety organizations.*
Charles River Labs to hedge fund: WuXi deal too good to pass up
Charles River Laboratories International Inc. (NYSE:CRL) responded to its largest shareholder’s protest about a proposed merger with Shanghai-based WuXi PharmaTech (Cayman) Inc. (NYSE:WX), saying the deal was too good to pass up.
In a letter to Jana Partners Inc. managing partner Barry Rosenstein, CRL CEO James Foster wrote that the hedge fund’s view of the proposed deal’s "strategic business benefits and attendant shareholder value proposition" are at odds with his company’s.
Florida woman sues DePuy Orthopedics over hip implant
DePuy Orthopaedics is facing the first of what might be an avalanche of lawsuits over one of its hip implants, after a Florida woman sued the company over an allegedly faulty hip implant.
More turmoil for China’s SFDA
Three years ago, China executed the former head of its State Food & Drug Administration after he was found guilty of taking bribes. The agency’s problems continue, however, as one of its deputy chiefs was fired and is under investigation for unspecified "disciplinary violations."
Healthcare “matchmaker” WellClicks raises $1 million
WellClicks, a startup that promises to match consumers with health providers, raised $1 million from seven investors in an equity offering, according to a filing with the Securities & Exchange Commission.
WellClicks isn’t looking to raise any more cash at the moment, COO and co-founder Mark Prondzinski said.
AtriCure wins 510(k) clearance for anti-clot device
AtriCure Inc. (NSDQ:ATRC) won 510(k) clearance from the Food & Drug Administration for its AtriClip device, which protects against blood clots during heart procedures.
The news sent AtriCure’s stock soaring 17 percent, to $6.13, in early after-hours trading June 14.
The West Chester, Ohio-based company plans an initial launch of the device later this month, with a full commercial release coming in the third quarter, according to a press release.